特宝生物：派格宾作为全球首个以乙肝临床治愈为治疗目标的药物，未来将根据经营情况进一步拓展国际业务

Group 1 - The core viewpoint of the article highlights the potential of Pegbivac to assist more hepatitis B patients in achieving higher treatment goals, as it is the world's first drug aimed at the clinical cure of hepatitis B [1] - The company plans to further expand its international business based on operational conditions in the future [1] - The inquiry from investors reflects the growing interest in overseas business development in the Chinese pharmaceutical industry [1]